Compounding Chemotherapy Market Size Forecast: $7.74 Billion by 2029 | Global Outlook

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What Is the Projected Market Size Valuation of the Compounding Chemotherapy Market by 2025?
The market for compounding chemotherapy has demonstrated vigorous growth in the past few years. The market value is predicted to rise from $5.74 billion in 2024 to $6.11 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.3%. Factors, such as escalating occurrence of cancer, increased utilization of hospital pharmacies, heightened usage of antineoplastic agents, a growing emphasis on patient-specific dosage, and the expansion role of oncology specialty clinics, are contributing to the historical growth.

What Is the Estimated Market Growth Value for the Compounding Chemotherapy Industry in 2029?
The market for compounding chemotherapy is projected to witness substantial growth over the next few years. It is estimated to expand to $7.74 billion by 2029, registering a compound annual growth rate (CAGR) of 6.1%. The predicted growth in the forecast period is influenced by factors such as an increased emphasis on precision medicine, a growing demand for both oral and injectable chemotherapy compounds, a heightened use of hormonal and biologic agents in cancer treatment, a move toward minimizing drug wastage, as well as a surge in need for targeted cancer therapies. Future trends that will shape this period include the adoption of technology in automated compounding machines, the creation of custom chemotherapy dosing protocols, the development of mobile applications aiding chemotherapy workflow, the merger of electronic health records (EHRs) with compounding practices, and incorporating barcode verification into compounding procedures.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/compounding-chemotherapy-global-market-report

What Are the Growth Drivers and Opportunities in the Compounding Chemotherapy Market?
The surging number of cancer incidences is set to boost the expansion of the compounding chemotherapy market in the future. Cancer denotes a series of conditions marked by the unchecked development and dissemination of abnormal body cells. The escalating occurrence of cancer is mainly attributed to unhealthy habits, like improper nutrition, sedentary lifestyle, smoking, excessive drinking, and long-term contact with environmental pollutants that tremendously inflate the chances of developing different cancer types. Compounding chemotherapy contributes to cancer therapy by offering personalized medication blends suited to each patient's requirements, enhancing effectiveness and reducing side effects. For instance, data from the Australian Institute of Health and Welfare, a government organization in Australia, indicated that in July 2024, there were 160,570 identified cancer cases in Australia for the year 2022. This number depicts a rise of 3,789 cases compared to the 156,781 cases in 2021. Thus, the escalating number of cancer incidences stimulates the expansion of the compounding chemotherapy market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25724&type=smp

What Are the Primary Segments Covered in the Global Compounding Chemotherapy Market Report?
The compounding chemotherapy market covered in this report is segmented -

1) By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs
2) By Route Of Administration: Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal
3) By Technology: With Robotic Arms, Without Robotic Arms
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings

Subsegments:
1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Topoisomerase Inhibitors
2) By Hormonal Agents: Estrogen Antagonists, Androgen Deprivation Therapy Agents, Aromatase Inhibitors, Progestins, Gonadotropin-Releasing Hormone Agonists
3) By Immunomodulatory Agents: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Interleukins, Cytokines, Immune System Activators
4) By Targeted Therapies: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors
5) By Supportive Care Drugs: Antiemetics, Erythropoiesis-Stimulating Agents, Bone-Modifying Agents, Pain Management Drugs

What Are the Top Growth Trends in the Compounding Chemotherapy Market?
Companies majorly participating in the compounding chemotherapy market are centering their efforts on developing novel solutions like robotic chemotherapy automation systems. These advancements aim to boost precision, safety, and efficiency in customised cancer treatment procedures. Robotics employed in chemotherapy automation systems are engineered to safely and accurately prepare personalised chemotherapy doses by automating the compounding procedures, hence reducing chances of human errors and contamination. As an example, an Israel-based health technology firm Simplivia Healthcare Ltd. launched the Smart Compounders Advanced Systems in February 2024. These systems specialize in the compounding of cytostatics and antibodies, able to manage 20 to 40 preparations per hour. They utilize automatic gravimetric verification and documentation to ensure impeccable precision. Furthermore, they greatly reduce the pharmacists' exposure to harmful substances. The systems are tailored to easily fit into existing laminar airflow (LAF) enclosures or isolators, without the need for modifications.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25724&type=smp

Which Companies Are Shaping the Future of the Compounding Chemotherapy Market?
Major companies operating in the compounding chemotherapy market are Baxter International Inc., Fresenius Kabi AG, Grifols S.A., Option Care Health Inc., ICU Medical Inc., Dedalus S.p.A., Fagron NV, BioScrip Inc., B. Braun Melsungen AG, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Icon Group Holdings Pty Ltd, Avella Specialty Pharmacy, Stokes Healthcare Inc, McGuff Compounding Pharmacy Services Inc., Accord Healthcare Limited, Epicur Pharma LLC, Simplivia Healthcare Ltd., AmerisourceBergen Corporation, Kapsam Health Products Ltd., PharMEDium Services LLC.

Which Region Holds the Largest Market Share in the Compounding Chemotherapy Industry?
North America was the largest region in the compounding chemotherapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the compounding chemotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.